Diagnostic and prognostic values of contrast‑enhanced ultrasound combined with diffusion‑weighted magnetic resonance imaging in different subtypes of breast cancer Retraction in /10.3892/ijmm.2020.4484

Liu,Gui‑Feng; Wang,Zong‑Qiang; Zhang,Shu‑Hua; Li,Xue‑Feng; Liu,Lin; Miao,Ying‑Ying; Yu,Shao‑Nan

doi:10.3892/ijmm.2018.3591

Diagnostic and prognostic values of contrast‑enhanced ultrasound combined with diffusion‑weighted magnetic resonance imaging in different subtypes of breast cancer

Retraction in: /10.3892/ijmm.2020.4484

Authors:
- Gui‑Feng Liu
- Zong‑Qiang Wang
- Shu‑Hua Zhang
- Xue‑Feng Li
- Lin Liu
- Ying‑Ying Miao
- Shao‑Nan Yu
View Affiliations

Affiliations: Department of Radiology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Medical Department, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Operation Room, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Anesthesiology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: March 27, 2018 https://doi.org/10.3892/ijmm.2018.3591
Pages: 105-114
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the diagnostic and prognostic values of contrast‑enhanced ultrasound (CEUS) combined with diffusion‑weighted magnetic resonance imaging (DW‑MRI) in different subtypes of breast cancer (BC). CEUS and DW‑MRI were conducted in 232 patients with BC prior to surgical treatment. Patients were categorized as having the luminal A subtype, the luminal B subtype, triple‑negative subtype or the human epidermal growth factor receptor 2 (Her‑2)‑positive subtype according to their expression of the estrogen receptor (ER), progesterone receptor (PR) and Her‑2, as detected by immunohistochemistry. The CEUS and DW‑MRI parameters of patients with different subtypes of BC were obtained and analyzed. The risk factors for the prognosis of patients with different subtypes of BC were analyzed using Kaplan‑Meier and COX regression analyses. The diagnostic accuracy rate of CEUS combined with DW‑MRI (93.10%) was higher than that of CEUS (88.79%) or DW‑MRI (82.33%) alone. The local recurrence rate and distant metastasis rate of the Her‑2‑positive subtype were the highest among all the subtypes. Furthermore, patients with Her‑2‑positive BC exhibited a higher proportion of lesions with indistinct margins and histological grade III. Lymph node metastasis and BC subtype were independent risk factors for the prognosis of BC. The overall survival and disease‑free survival of patients with the luminal A subtype were higher than those of patients with the Her‑2‑positive subtype. The results of the current study therefore indicate that CEUS combined with DW‑MRI is more effective at diagnosing the different subtypes of BC than either CEUS or DW‑MRI alone.

View Figures

View References

1	Farzaneh F, Noghabaei G, Barouti E, Pouresmaili F, Jamshidi J, Fazeli A, Emamalizadeh B and Darvish H: Analysis of CYP17, CYP19 and CYP1A1 gene polymorphisms in Iranian women with breast cancer. Asian Pac J Cancer Prev. 17:23–26. 2016. View Article : Google Scholar : PubMed/NCBI
2	Zhao YX, Liu S, Hu YB, Ge YY and Lv DM: Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: A retrospective study. Onco Targets Ther. 10:1123–1129. 2017. View Article : Google Scholar : PubMed/NCBI
3	Ghoncheh M, Pournamdar Z and Salehiniya H: Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 17:43–46. 2016. View Article : Google Scholar : PubMed/NCBI
4	Fan L, Strasser-Weippl K, Li JJ, St Louis J , Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast cancer in China. Lancet Oncol. 15:e279–e2892014. View Article : Google Scholar : PubMed/NCBI
5	Huang Z, Wen W, Zheng Y, Gao YT, Wu C, Bao P, Wang C, Gu K, Peng P, Gong Y, et al: Breast cancer incidence and mortality: Trends over 40 years among women in Shanghai, China. Ann Oncol. 27:1129–1134. 2016. View Article : Google Scholar : PubMed/NCBI
6	Graudenzi A, Cava C, Bertoli G, Fromm B, Flatmark K, Mauri G and Castiglioni I: Pathway-based classification of breast cancer subtypes. Front Biosci. 22:1697–1712. 2017. View Article : Google Scholar
7	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
8	Clinicopathological features of nonspecific invasive breast cancer according to its molecular subtypes. Exp Oncol. 38:122–127. 2016.PubMed/NCBI
9	Yuan ZY, Wang SS, Zhu MQ, Zheng L, Luo WB, Zhou ZM and Guan ZZ: Clinical characteristics and prognosis of different subtypes of breast cancer. Zhonghua Zhong Liu Za Zhi. 30:456–461. 2008.In Chinese. PubMed/NCBI
10	Hoyt K, Warram JM, Umphrey H, Belt L, Lockhart ME, Robbin ML and Zinn KR: Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks. J Ultrasound Med. 29:577–585. 2010. View Article : Google Scholar : PubMed/NCBI
11	Xu HX and Lu MD: The current status of contrast-enhanced ultrasound in China. J Med Ultrason. 37:97–106. 2010. View Article : Google Scholar
12	Cao XL, Bao W, Zhu SG, Wang LH, Sun MH, Wang L, Men YM and Xue J: Contrast-enhanced ultrasound characteristics of breast cancer: Correlation with prognostic factors. Ultrasound Med Biol. 40:11–17. 2014. View Article : Google Scholar
13	Szabó BK, Saracco A, Tánczos E, Aspelin P, Leifland K, Wilczek B and Axelsson R: Correlation of contrast-enhanced ultrasound kinetics with prognostic factors in invasive breast cancer. Eur Radiol. 23:3228–3236. 2013. View Article : Google Scholar : PubMed/NCBI
14	Wang JW, Zheng W, Liu JB, Chen Y, Cao LH, Luo RZ, Li AH and Zhou JH: Assessment of early tumor response to cytotoxic chemotherapy with dynamic contrast-enhanced ultrasound in human breast cancer xenografts. PLoS One. 8:e582742013. View Article : Google Scholar : PubMed/NCBI
15	Jia WR, Tang L, Wang DB, Chai WM, Fei XC, He JR, Chen M and Wang WP: Three-dimensional contrast-enhanced ultrasound in response assessment for breast cancer: A Comparison with dynamic contrast-enhanced magnetic resonance imaging and pathology. Sci Rep. 6:338322016. View Article : Google Scholar : PubMed/NCBI
16	Heusner TA, Kuemmel S, Koeninger A, Hamami ME, Hahn S, Quinsten A, Bockisch A, Forsting M, Lauenstein T, Antoch G and Stahl A: Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging. 37:1077–1086. 2010. View Article : Google Scholar : PubMed/NCBI
17	Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B and Menu Y: Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: Prospective study in 66 patients. Radiology. 226:71–78. 2003. View Article : Google Scholar : PubMed/NCBI
18	Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, et al: Diffusion-weighted magnetic resonance imaging as a cancer biomarker: Consensus and recommendations. Neoplasia. 11:102–125. 2009. View Article : Google Scholar : PubMed/NCBI
19	Carlson RW: NCCN breast cancer clinical practice guidelines in oncology: An update. J Natl Compr Cancer Netw. 1(Suppl 1): S61–S63. 2003.
20	Qian XL, Wen HY, Yang YL, Gu F, Guo XJ, Liu FF, Zhang L, Zhang XM and Fu L: Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines. Breast Cancer Res Treat. 159:31–39. 2016. View Article : Google Scholar : PubMed/NCBI
21	Liu FS: Histological grading and prognosis of breast cancer. Zhonghua Bing Li Xue Za Zhi. 22:36–37. 1993.In Chinese. PubMed/NCBI
22	Kawashima H, Miyati T, Ohno N, Ohno M, Inokuchi M, Ikeda H and Gabata T: Differentiation between luminal-A and luminal-B breast cancer using intravoxel incoherent motion and dynamic contrast-enhanced magnetic resonance imaging. Acad Radiol. 24:1575–1581. 2017. View Article : Google Scholar : PubMed/NCBI
23	Jiang Q, Hao S, Xiao X, Yao J, Ou B, Zhao Z, Liu F, Pan X, Luo B and Zhi H: Production and characterization of a novel long-acting Herceptin-targeted nanobubble contrast agent specific for Her-2-positive breast cancers. Breast Cancer. 23:445–455. 2016. View Article : Google Scholar :
24	Youk JH, Son EJ, Chung J, Kim JA and Kim EK: Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: Comparison with other breast cancer subtypes. Eur Radiol. 22:1724–1734. 2012. View Article : Google Scholar : PubMed/NCBI
25	Wang R, Chen JJ, Zhou YC, Huang MM, Zhang XR and Miao HD: Evaluation of diffusion-weighted magnetic resonance imaging and contrast-enhanced harmonic ultrasonography in detection and location of prostate transition-zone cancer. J Int Med Res. 39:256–266. 2011. View Article : Google Scholar : PubMed/NCBI
26	Yang Q, Chen J, Li HJ, Yu M, Tian CX and Lü Q: Clinical features and prognosis analysis of different breast cancer molecular subtypes. Zhonghua Zhong Liu Za Zhi. 33:42–46. 2011.In Chinese. PubMed/NCBI
27	Liu AN, Sun P, Liu JN, Ma JB, Qu HJ, Zhu H, Yu CY and Zhang LM: Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer. Asian Pac J Cancer Prev. 13:1197–1201. 2012. View Article : Google Scholar : PubMed/NCBI
28	de Boer M, van Dijck JA, Bult P, Borm GF and Tjan-Heijnen VC: Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst. 102:410–425. 2010. View Article : Google Scholar : PubMed/NCBI
29	Wu SG, Sun JY, Yang LC, Tang LY, Wang X, Chen XT, Liu GH, Lin HX, Lin Q and He ZY: Patterns of distant metastasis in Chinese women according to breast cancer subtypes. Oncotarget. 7:47975–47984. 2016.PubMed/NCBI
30	Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277. 2010. View Article : Google Scholar : PubMed/NCBI
31	Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, et al: Prognosis of metastatic breast cancer subtypes: The hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 141:507–514. 2013. View Article : Google Scholar : PubMed/NCBI
32	Zhao J, Liu H, Wang M, Gu L, Guo X, Gu F and Fu L: Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Surg Oncol. 100:89–94. 2009. View Article : Google Scholar : PubMed/NCBI
33	Coates AS, Colleoni M and Goldhirsch A: Is adjuvant chemotherapy useful for women with luminal a breast cancer. J Clin Oncol. 30:1260–1263. 2012. View Article : Google Scholar : PubMed/NCBI
34	Finetti P, Cervera N, Charafe-Jauffret E, Chabannon C, Charpin C, Chaffanet M, Jacquemier J, Viens P, Birnbaum D and Bertucci F: Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res. 68:767–776. 2008. View Article : Google Scholar : PubMed/NCBI
35	Kim HS, Park I, Cho HJ, Gwak G, Yang K, Bae BN, Kim KW, Han S, Kim HJ and Kim YD: Analysis of the potent prognostic factors in luminal-type breast cancer. J Breast Cancer. 15:401–406. 2012. View Article : Google Scholar
36	Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
37	Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J, Torrella-Ramos A, Martos C, Ardanaz E, Chirlaque MD, Perucha J, Díaz JM, Mateos A, et al: Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Gynecol Oncol. 130:609–614. 2013. View Article : Google Scholar : PubMed/NCBI
38	Wang GS, Zhu H and Bi SJ: Pathological features and prognosis of different molecular subtypes of breast cancer. Mol Med Rep. 6:779–782. 2012. View Article : Google Scholar : PubMed/NCBI